Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Blenrep (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody-drug conjugate (ADC). It is indicated, in combination with bortezomib and dexamethasone, for the treatment of adults with:
Blenrep received FDA approval for this combination in October 2025, supported by Phase III data showing improved overall survival compared to standard therapy. (An earlier, different Blenrep monotherapy approval was voluntarily withdrawn by GSK in 2022 after its confirmatory trial did not meet its primary endpoint — the current approval reflects new data with this combination regimen.) It is a prescription oncology medicine and must be used under the supervision of a qualified hematologist-oncologist.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Boxed Warning — Ocular Toxicity: Blenrep causes changes in the corneal epithelium that can alter vision, including severe vision loss and corneal ulcers, along with symptoms such as blurred vision and dry eyes. Because of this risk, Blenrep is only available through a restricted distribution program (the BLENREP REMS).
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Blenrep (belantamab mafodotin-blmf) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Blenrep (belantamab mafodotin-blmf injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Blenrep is not commercially marketed in India.
However, patients in India can legally access Blenrep through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Blenrep received US FDA approval for its current combination-therapy indication in October 2025, ensuring full transparency throughout the process.
Blenrep can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) can source Blenrep from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Blenrep requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C until use. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Blenrep cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Blenrep through regulated import pathways, with delivery arranged to the treating hospital based on a valid oncologist's prescription.
A major oncology hub with institutions like Tata Memorial, Mumbai coordinates access to advanced myeloma therapies like Blenrep for eligible patients.
As part of the Delhi NCR region, the city has a strong concentration of cancer centers, making it a key location for accessing multiple myeloma treatments.
With a growing network of multispecialty oncology hospitals, Bangalore supports access to Blenrep through structured import pathways guided by treating specialists.
Home to several reputed cancer treatment centers, Chennai facilitates access to Blenrep for patients with relapsed or refractory multiple myeloma.
A growing hub for oncology care, Hyderabad supports coordinated access to Blenrep for eligible patients under specialist supervision.
Eastern India's leading cancer centers in Kolkata coordinate Blenrep access for patients with advanced myeloma.
With an expanding base of oncology clinics, Pune facilitates timely access to Blenrep under prescription.
Gujarat's leading cancer hospitals support regulated access to Blenrep for eligible patients.
Kerala's healthcare network, including major cancer centers in Kochi, coordinates access to advanced targeted therapies like Blenrep.
Serving North India, Chandigarh's oncology centers facilitate access to Blenrep for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Blenrep through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Blenrep under oncologist care.
Odisha's growing oncology sector supports patient access to Blenrep.
As a referral hub for the North-East, Guwahati facilitates access to Blenrep for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
